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The Involvement of DNA-Damage and -Repair Defects
in Neurological Dysfunction
Avanti Kulkarni1 and David M. Wilson III1,*
A genetic link between defects in DNA repair and neurological ab-
normalities has been well established through studies of inherited
disorders such as ataxia telangiectasia and xeroderma pigmento-
sum. In this review, we present a comprehensive summary of
the major types of DNA damage, the molecular pathways that
function in their repair, and the connection between defective
DNA-repair responses and speciﬁc neurological disease. Particular
attention is given to describing the nature of the repair defect and
its relationship to the manifestation of the associated neurological
dysfunction. Finally, the review touches upon the role of oxidative
stress, a leading precursor to DNA damage, in the development of
certain neurodegenerative pathologies, such as Alzheimer’s and
Parkinson’s.
Introduction
DNA damage is an underlying cause of cellular dysfunction
and death, carcinogenesis, and the aging process. Every
day, cells’ genomes endure on average approximately one
million lesions, including bulky helix-distorting adducts
and modiﬁcations or fragmentation of the sugar phos-
phate backbone. Left unrepaired, DNA damage can drive
mutagenesis (e.g., base substitutions, transitions, transver-
sions, frameshifts or chromosomal translocations), disrupt
normal gene expression, or create aberrant protein prod-
ucts that are detrimental to cellular function or viability.
To cope with such damage, cells are equipped with a myr-
iad of DNA-repair enzymes and pathways. Defects in one
or more of the essential components of these pathways
can lead to the propagation of genomic instability. In rep-
licating cells, such instability can result in apoptosis (a
mechanism for removing abnormal cells) or cellular trans-
formation (a key step in the development of cancer). In
nonreplicating terminally differentiated cells, such as neu-
ronal tissue, the loss of genomic integrity often leads to cell
death via apoptosis and, consequently, to tissue degenera-
tion and atrophy. In recent years, increasing attention has
been paid to the role that DNA damage and repair play in
neurological disease.
Several neurodegenerative disorders are directly or indi-
rectly linked to defects in DNA single-strand break (SSB)
repair (SSBR) or double-strand break (DSB) repair (DSBR).
A number of these disorders adversely affect the operation
of the cerebellum, which is the part of the brain responsi-
ble for coordination of muscular movement and for the
maintenance of posture and balance. In addition, the cer-
ebellum coordinates non-motor functions such as cogni-
tion and emotions. Given the central role the cerebellum
plays in motor-sensory perception, it follows that damage
to this part of the brain manifests itself in the form of
in-coordination of speech, thought, and movement; col-
lectively, such damage is termed ataxia. In this review, we
will summarize the neurological abnormalities related to
SSBR, DSBR, and nucleotide excision repair (NER) defects.
Given that the road to genomic stability and cell viability
is so intricately linked with DNA damage and repair, we be-
gin with a comment on the predominant sources of DNA
damage, the lesions that result, and the repair pathways
that function in their removal.
Sources of DNA Damage
DNA damage can be classiﬁed into two types: endogenous
and exogenous. As deﬁned herein, endogenous damage is
that caused by agents within the cell itself (i.e., the prod-
ucts of normal cellular metabolism). Exogenous damage,
on the other hand, refers to damage caused by physical
or chemical agents in the environment. Spontaneous en-
dogenous DNA damage typically occurs at a higher fre-
quency than exogenous damage, but in developed socie-
ties, exogenous factors from accidental or involuntary
exposures contribute to 75%–80% of cancer cases.1–3 Nota-
bly, both modes of damage can result in similar types of
DNA lesions and genetic outcomes. It is important to
emphasize that in most cases there is no direct evidence
linking exogenous damage (e.g., that induced by external
radiation) to neurological disease, and thus, endogenous
damage is considered most relevant in terms of disease
manifestation. However, for the sake of completeness, out-
lined below are the principal agents that contribute to en-
dogenous and exogenous damage and some of the main
lesions they create. Collectively, these sources generate
a high number of DNA modiﬁcations (see Table 1), which
if left unrepaired can be detrimental to the cell and, ulti-
mately, to the organism.
1. Endogenous Damage
Reactive Oxygen Species. Reactive oxygen species (ROS),
which include species such as singlet oxygen atoms, hy-
droxyl radicals, superoxide radicals, and hydrogen perox-
ide, are generated as by-products of normal mitochondrial
respiration,4 during conditions of chronic inﬂamma-
tion,5,6 or as discussed below, upon exposure to certain
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environmental agents. These reactive chemicals are usu-
ally neutralized by cellular defense systems, which include
ROS-scavenging enzymes (superoxide dismutase and cata-
lase), antioxidant enzymes (glutathione reductase and glu-
tathione peroxidase) and vitamins (E and C).7 However, in
situations when the generation of ROS exceeds the cell’s
antioxidant capacity (i.e., during conditions of oxidative
stress), ROS amass and attack macromolecules such as
lipids, proteins, and DNA. In the case of DNA, ROS react
with both purines and pyrimidines to generate modiﬁed
bases such as 8-oxoguanine (8-oxo-dG), 5-hydroxyuracil,
uracil glycol, 5-hydroxymethylthymidine, 5-hydroxyme-
thyluracil, cytosine glycol, 2,6-diamino-4-oxy-5-formami-
dopyrimidine (FAPY) adenine, FAPY guanine, and thymine
glycol, to name a few.1 Other frequent lesions arising from
ROS attack of the sugar phosphate backbone include abasic
sites and DNA strand breaks. Such lesions, as will be dis-
cussed later, are also products of enzymatic processing of
oxidized bases during repair.8,9
Aldehydes, Estrogens, and Reactive Carbonyl Species. ROS-
mediated lipid peroxidation, glucose metabolism, and
estrogen metabolism are some of the processes that lead
to the production of reactive aldehydes. The aldehydic
by-products of lipid peroxidation, i.e., crotonaldehyde,
acrolein, 4-hydroxynonenal (HNE), and malondialdehyde
(MDA), form exocyclic ethano and propane base adducts
in DNA that can block base pairing and are highly muta-
genic.10,11 Oxidation of sugars, such as glucose, and sugar
metabolism itself creates reactive carbonyl species, e.g.,
glyoxal and methylglyoxal, which can produce carcino-
genic base adducts such as glyoxalated deoxycytidine.12,13
Estrogen metabolism generates metabolites such as cate-
chol estrogens (CEs). If incompletely inactivated by endog-
enous processes, such metabolites can undergo oxidation
Table 1. Endogenous DNA Damage
Source of
Damage
Mechanism of
Formationa Type of Damage Lesionsb
Measured Levels of
Damage or Rates of
Formation Tissue Reference
ROS (reactive
oxygen species)
mitochondrial
respiration; glucose
metabolism; estrogen
metabolism; chronic
inflammation; muscle
contraction; vascular
function;
neurotransmission
oxidized bases and
phosphodiester
backbone products
50-hydroxy-20-dC 1.02/106 nt leukocytes 29
50-hydroxy-20-dU 0.69/106 nt
RCS (reactive
carbonyl species)
glycation; oxidation
of sugars; breakdown
of lipid
hydroperoxides
bulky base adducts;
cross links; base
deamination
products
MG-30-dGMP (3-(20-
deoxy-b-D-erythro-
pentafuranosyl)-6,
7-dihydro-6,7-
dihydroxy-6-
methylimidazo[2,3-
b]purine-9(8H)one)
0.26/106 nt buccal
epithelial cells
28,24
malonaldehyde-dG 5400/cell liver
alkylators choline metabolism;
S-adenosyl
methionine (SAM)
alkylated bases O6 methyl guanine 0.022–0.13/106 nt liver 25,27
O4 alkylthymidines 0.003–4.24/106 nt liver
7-alkylguanines 1.31/106 nt leucocytes
catechol
estrogens
steroid metabolism bulky depurinating
adducts; oxidized
bases
4-hydroxy catechol
estradiol-1(a,b)-
N7 guanine
1.4–2.3 mmol/mol
DNA phosphate
rat mammary
gland
14
aldehydes lipid peroxidation;
glycation; estrogen
metablosim;
prostaglandin
biosynthesis
bulky base adducts MIG (dG pyrimido[1,2-
a]purin-10(3H)-one)
0.14/106 nt liver 30,10
HNE-dG (4-
hydroxynonenal-dG)
0.0006–0.0018/106 nt
spontaneous
hydrolytic
deamination
enhanced by
thermal
fluctuations
modified bases modified bases uracil,
hypoxanthine,
xanthine
100–500 cytosine-
uracil/cell/day
in vitro determination
on isolated DNA as
a function of pH and
temperature
22
spontaneous
depurination
enhanced by thermal
fluctuations or base
modification
sites of base loss abasic sites ~4/106 nt lymphoblastoid cell
line H2EI
26
8–9/106 nt liver
a Represent some of the primary endogenous pathways and processes that generate the damaging agent indicated.
b Representative lesions. For a more comprehensive list of lesions and their frequencies, refer to the review by Rinne De Bont et al.1
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to form quinones and semiquinones (CE-Q and CE-SQ,
respectively). The redox cycling of quinone moieties can
generate additional ROS.14,15 CE-Q moieties are also capa-
ble of directly attacking DNA to create bulky depurinating
adducts (e.g., estrogen-DNA adducts and estradiol-induced
MDA adducts).
Alkylators. Another class of endogenous DNA-damaging
agents includes alkylators, such as nitrosated bile salts,
which are formed by bile acids that act upon N-nitroso
compounds (found in nitrite-treated meat products or
food),16 and S-adenosyl methionine (SAM). SAM is a natu-
ral reactive methyl-group donor for a variety of enzymatic
reactions involving a range of acceptor molecules.17,18
SAM can inappropriately alkylate DNA bases to generate
products such as 7-methylguanine, 3-methyladenine, and
N7-carboxymethylguanine, which can be mutagenic or
interfere with DNA replication or transcription.19,20 On
the basis of in vitro studies, it has been estimated that
SAM-mediated alkylation accounts for approximately
4000 7-methylguanine, 600 3-methyladenine, and 10–30
O6-methylguanine residues per mammalian genome per
day. Abasic sites are also prominent intermediates of alkyl-
ation base damage; these result from enzymatic base
removal during repair (see below) or from spontaneous
depurination of the hyper-labile glycosidic bond between
the modiﬁed base and the sugar moiety.21–23
Intrinsic Instability of DNA. In addition to being under
constant attack from endogenous sources, the chemical
structure of DNA is susceptible to spontaneous decay. For
instance, pyrimidines and purines endure spontaneous
hydrolytic deamination; cytosines and 5-methylcytosines
are particularly susceptible (100–500 cytosines are sponta-
neously deaminated/cell/day to form uracil).22 Purine
deamination is less frequent; adenine is deaminated to hy-
poxanthine and guanine to xanthine at about 2%–3% the
rate of cytosine deamination.1,22 Such deamination events
eventually lead to the creation of abasic sites after the en-
zymatic removal of the nonconventional base moiety via
a repair response (see below). Apurinic/apyrimidinic (AP)
sites are also frequent products of spontaneous hydrolysis
of the N-glycosidic bond that links the base to the sugar
phosphate backbone; such hydrolysis arises an estimated
10,000 times per human genome per day under normal
physiological conditions.22 An overview of the main sour-
ces of endogenous DNA damage, examples of the lesions
produced, and the measured frequencies of occurrence
are presented in Table 1.1,10,14,22,24–30
2. Exogenous Damage
Physical agents. Ionizing and non-ionizing radiation is the
most prominent environmental physical agent that dam-
ages DNA. Exposure to radiation can occur from both nat-
ural (cosmic rays from the sun, radioactive elements in the
environment, atmosphere, soil, plants and trees) and ar-
tiﬁcial (diagnostic X-rays, smoke detectors) sources. Most
ionizing radiation (IR)-induced DNA damage results from
reactions with hydroxyl radicals that are generated from
radiolysis of water, although some damage arises from
direct ionization of nucleic acid. IR-dependent DNA le-
sions include ‘‘simple’’ oxidative damage, such as modiﬁed
bases, SSBs or abasic sites, and more ‘‘complex’’ clustered
lesions (deﬁned as those damages within a helical turn of
one another) or DSBs.31,32 Non-IR-induced DNA damage
primarily involves ultraviolet (UV) radiation from the
sun. The ring-structure content and the conjugated bonds
in DNA bases make them prominent absorbers of both
short- and long-wave UV radiation. The most important
targets of UV light are adjacent pyrimidines that dimerize
to form helix-distorting photoproducts, e.g., thymidine
dimers.33,34 Again, we note that radiation-induced DNA
damage is not considered a major factor in the manifesta-
tion of neurological disease.
Chemical Agents. An array of genotoxic compounds are
found within the environment in air, soil, water, and
food. These include polluting heavy metals such as mer-
cury, arsenic, and cadmium, which can produce ROS that
create base modiﬁcations or SSBs;35 food-based carcino-
gens such as aﬂatoxin, found in oilseeds, nuts, and cereals
that react with DNA bases to form bulky adducts;36 and air
pollutants such as radon, air-borne ﬁne particulate matter,
and secondhand smoke, which can produce both oxida-
tive and alkylative stress.37 Exposure to these and other
environmental hazards has been linked epidemiologically
to increased incidence of cancer and, in some cases, neuro-
logical defects.35,38–41 In addition to inadvertent environ-
mental exposure, occupational exposure to DNA-damag-
ing agents such as mutagenic chemicals and drugs can
occur in certain industrial, laboratory, and clinical settings.
Finally, crosslinking agents such as cisplatin and base ana-
logs such as 50-ﬂuoro-deoxyuridine and 50-ﬂuorouracil are
routinely used in chemotherapy to ‘‘selectively’’ induce
DNA damage and apoptosis in rapidly dividing cancer
cells.42–44
Mechanisms of DNA Repair
As is evident from the above information, endogenous
and exogenous DNA-damaging agents can create modiﬁed
bases, abasic sites, SSBs, helix-distorting adducts, intra-
and inter-strand crosslinks, and/or DSBs. If left unrepaired,
these lesions can cause base transitions, transversions,
frameshift mutations, or gross chromosomal aberrations
and can induce cell death. Cells are equippedwith enzymes
that recognize and remove damaged bases or more com-
plex DNA lesions to prevent mutagenesis and the cellular
dysfunction that underlie cancer, neurodegeneration, and
other disease states. Discussednext are themajor cellular re-
pair pathways and the related enzymatic machinery that
operate to correct certain forms of DNA damage.
1. Excision Repair and SSB Processing
Threemajor pathways function in the removal of modiﬁed
bases, mismatches, and bulky adducts. These include base
excision repair (BER), mismatch repair (MMR), and NER,
respectively. Each of these processes proceeds via (1)
The American Journal of Human Genetics 82, 539–566, March 2008 541
removal of the substrate base, (2) formation of a SSB gap
at the excision site, and (3) re-establishment of the native
DNA content by pathway-speciﬁc polymerases and ligases.
Because all three repair mechanisms proceed via a SSB
intermediate, we discuss them together.
BER. BER functions during all stages of the cell cycle to
repair non-helix-distorting base modiﬁcations, abasic sites,
and various types of SSBs. Typically, the ﬁrst step in BER is
recognition and removal of an inappropriate base, such as
one created by ROS attack, alkylation, spontaneous hydro-
lysis (e.g., deamination of cytosine to uracil), or nucleotide
misincorporation (i.e., certain mismatches). Such removal
is performed by a class of enzymes called DNA glycosylases
(Figure 1). These proteins hydrolyze the N-glycosidic bond
to release the substrate base and create an abasic-site inter-
mediate.21,45,46 Glycosylases, such as uracil DNA glycosy-
lase (UNG [MIM 191525]) and 8-oxo-dG DNA glycosylase
(OGG1 [MIM 601982]), generally target speciﬁc kinds of
base damage, although these enzymes as a whole maintain
an overlapping complement of base substrates.46–50
Once an AP site has been generated, some DNA glycosy-
lases (e.g., OGG1) possess an AP lyase activity that cleaves
30 to the abasic residue to produce a SSB with a normal 50
phosphate group and an atypical 30 a, b unsaturated alde-
hyde.51 More commonly, however, the AP site is incised
by the action of a hydrolytic endonuclease, speciﬁcally
the major mammalian AP endonuclease APE1 (APEX
[MIM 107748]) (also called Hap1 or Ref1) (Figure 1). Such
Figure 1. Base Excision Repair
(i) Recognition and removal of a modified base by a DNA glycosylase, leaving behind an abasic site (shown is removal of deaminated
cytosine (uracil) by UNG).
(ii) Cleavage at the abasic site by APE1, creating a SSB with a 50 dRP and 30 hydroxyl (OH) end.
(iii) Gap filling at the strand break via either short-patch (left) or long-patch repair synthesis (right). In short-patch base excision repair
(BER), Pol b replaces the missing nucleotide, whereas in long-patch BER, Pol b, d, or 3 incorporates 2–10 nucleotides via strand displace-
ment (newly synthesized sequence in gray). PCNA and RPA assist in the process.
(iv) Excision of the 50 dRP to create ligatable ends is performed by the lyase activity of Pol b (short-patch BER) or the flap endonuclease
activity of FEN1 (long-patch BER).
(v) The final nick is sealed by Ligase IIIa in complex with XRCC1 (short patch BER) or by Ligase I (long patch BER) to regenerate the intact
strand.
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enzymes incise the phosphodiester bond 50 to an abasic
lesion and create a SSB with an abnormal 50–20-deoxyribose
phosphate (dRP) residue and a conventional 30-OH termi-
nus that can be extended by themajor gap-ﬁlling polymer-
ase, DNA polymerase b (Pol b) (POLB [MIM 174760]).52
APE1 also functions to remove the 30 a,b-unsaturated alde-
hydic blocking groups left behind by bifunctional DNA
glycosylases (see above) to create 30-OH priming ends.
After strand breakage, and appropriate 30-terminal clean
up if needed, BER proceeds via either a short-patch or
a long-patch repair reaction. In short-patch BER (Figure 1,
left), DNA Pol b adds a single nucleotide and removes the
50-dRP group, and DNA Ligase IIIa (LIG3 [MIM 600940])
(in complex with the X-ray cross-complementing 1
(XRCC1 [MIM 194360]) protein) seals the nick to complete
the process.51–58 In situations where the 50 terminus is not
a substrate for Polb, suchaswithcertainoxidizedor reduced
AP-site fragments,59,60 long-patch BER takes place to pro-
mote strand displacement and synthesize 2–10 nucleotides
(Figure 1, right). This repair reaction is performed by Pol b
or Pol d/3 (POLD1 [MIM 174761])/POLE [MIM 174762])
in concert with the 50-ﬂap endonuclease (FEN1 [MIM
600393]), proliferating cell nuclear antigen (PCNA [MIM
176740]) and DNA Ligase I (LIG1 [MIM 126391]).54,58,61–63
Recent studies onBERhave shown that certain 50 or 30 ob-
structive termini at SSBs are prepared for Pol b polymeriza-
tion and/ornick ligationbyproteins suchas polynucleotide
kinase/phosphatase (PNKP [MIM 605610]),64 Aprataxin
(APTX [MIM 606350]),65,66 and tyrosyl-DNA phosphodies-
terase (TDP1 [MIM 607198])67,68 (see more below). Finally,
a critical component of BER and its sub-pathway SSBR is the
scaffold protein XRCC1, which recruits several key enzy-
matic factors, including Pol b, Ligase IIIa, TDP1, and Apra-
taxin, to the site of the damage.68–75 Figure 1 summarizes
the major steps of the BER pathway.
MMR. MMR functions to remove mismatches and small
insertions or deletions that arise as replication errors or
during recombination.76 Mammalian MMR is initiated by
MutSa (comprised of MSH2 [MIM 609309] and MSH6
[MIM 600678]) or by MutSb (a MSH2-MSH3 [MIM
600887] heterodimer), which recognize single base mis-
matches and 1–2 nucleotide insertion-deletion (ID) mis-
matches (MutSa) and 2–10 nucleotide IDs (MutSb).76,77
MutLa (MLH1 [MIM 120436]:PMS2 [MIM 600259] hetero-
dimer) is then recruited and apparently serves to coordi-
nate other proteins, such as PCNA, at the damage site.78,79
Subsequent steps of MMR are facilitated by the concerted
actions of PCNA (strand discrimination), Exo1 (MIM
606063) (excision), replication protein A (RPA2 [MIM
179836]), Pol d, and a DNA ligase.76 Because none of the
components ofMMRhave been conclusively linked to neu-
rodegenerative disease to date, this repair systemwill not be
discussed in further detail. For a comprehensive review of
MMR, the reader is directed to reviews by Buermeyer et al.
and Modrich.76,80
NER. NER functions largely independently of the cell
cycle to remove bulky DNA adducts, such as UV-induced
cyclobutane pyrimidine dimers, DNA crosslinks, and
certain oxidative base modiﬁcations, and is divided into
two sub-pathways: global genome repair (GGR) and tran-
scription-coupled repair (TCR) (Figure 2). As the names
suggest, GGR deals with lesions present throughout the
genome, whereas TCR handles DNA damage that blocks
RNA polymerase elongation during gene transcription. As
described in greater detail later, many of the key factors
operating in NER have been associated with the cancer-
prone disorder xeroderma pigmentosum (XP) and the
segmental progeria cockayne syndrome (CS), which both
display elements of neurological dysfunction in a sub-set
of individuals.
GGR (Figure 2, left) is initiated by recognition of the
helix-distorting adduct by an XPC (MIM 278720)-HR23B
(MIM 600063) complex.81 This is followed by recruitment
of XPA (MIM 611153), RPA, and the other components of
the general transcription factor TFIIH to the lesion site.
This multi-subunit assembly establishes the pre-incision
complex.82–85 TFIIH is comprised of two helicases, XPB
(MIM 610651) and XPD (MIM 278730), Cdk-activating ki-
nases (Cdk7 [MIM 601955] and cyclin H [MIM 601953]/
Mat1), and DNA-binding proteins (p34 and p44), all of
which serve to unwind the duplex at the lesion site and
create a small bubble structure.83 Unwinding is followed
by dual incision on either side of the damage by XPG
(MIM 278780) (incision at the 30 bubble-duplex junction)
and the XPF (MIM 278760)-ERCC1 (MIM 126380) com-
plex (incision 50) to release a short single-stranded DNA
segment (27–39 nucleotides) that contains the lesion.86–89
Repair synthesis at the resulting gap is carried out by
Pol d/3 in coordination with RPA/PCNA/RFC (replication
factor C) and is followed by DNA Ligase I-mediated nick li-
gation.58,83,90 Recent evidence also implicates XRCC1-Li-
gase IIIa in the sealing of nicks during NER, particularly
in quiescent cells.91
With the exception of the initiating mechanism, TCR
proceeds in a manner similar to GGR and involves many
of the same protein components.92 Damage recognition
and processing in TCR is initiated when an RNA polymer-
ase stalls at a lesion site and thus initiates recruitment of CS
proteins CSA (MIM 216400) and CSB (MIM 133540). The
exact function of CSA is not known, but it is reported to
translocate to the nuclear matrix in a CSB-dependent man-
ner after UV irradiation or exposure to hydrogen peroxide.
This translocation is independent of XPA and XPC, indi-
cating that it is speciﬁc to TCR.93,94 CSA is reportedly
linked to a ubiquitin ligase complex and might play
a role in ubiquitylation of the RNA polymerase during
TCR by tagging the polymerase for degradation to allow
for unimpeded repair. Recent evidence also suggests that
CSB might be a substrate for the ubiquitin ligase complex
and that it is degraded in a CSA-dependent manner during
a late stage of the repair response, presumably to permit
resumption of transcription.95,96 CSB is a member of the
SWI2/SNF2 family and has DNA-dependent ATPase and
ATP-dependent chromatin remodeling activities. It is part
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of the RNA polymerase II (RNAPII) transcription machin-
ery and recruits various NER components to the stalled
RNAPII during TCR, although its precise biochemical
function in the process remains unclear.97–99 CSA and
CSB have been speculated to play a role in the removal
of oxidative lesions during TCR as well; however, this is
currently controversial. More recent evidence implicates
these proteins in global repair of oxidative DNA dam-
age.100–102 The detailed biochemistry of the early steps of
TCR are presently being reﬁned, but for a more complete
perspective refer to De Laat et al., Mellon et al., and Van
Hoffen et al.83,92,103
2. DSBR
DNADSBs take on two forms: two-ended breaks, generated
primarily by direct attack onDNAby a physical or chemical
mutagen such as IR, or one-ended breaks, created upon rep-
lication-fork collapse at sites of DNA damage (e.g., SSBs).
Three major pathways function to repair two-ended DSBs:
homologous recombination (HR), which entails faithful
exchange between regions of homology on sister chroma-
tids and engages the DNA-replication machinery; single-
strand annealing (SSA), which involves annealing between
complementary single-stranded segments of the samechro-
mosome on either side of the DSB; and nonhomologous
end-joining (NHEJ), which involves direct ligation of
processed DSB ends. The one-ended, replication-derived
DSBs appear to be resolved strictly by classical HR involving
sister chromatids. Discussed next are the mechanistic de-
tails of these pathways. It is important to keep in mind
that the process of DSBR involves dynamic interplay be-
tween phases of recognition, cell signaling (the response),
and ﬁnally, break resolution.
HR and SSA. The process of HR involves exchange of ge-
netic information between complementary regions of two
homologous chromosomes (typically sister chromatids)
that are aligned for crossover (Figure 3A). It is largely an
error-free form of repair and hence integral to the
Figure 2. Nucleotide Excision Repair
(i) Recognition and removal of helix-distorting adducts (e.g., thymine dimer, shown) is mediated by the XPC-HR23B complex in global
genomic repair (left) or by a stalled RNAP II-CSB complex during transcription-coupled repair (right). Subsequent repair steps are similar
for both GGR and TCR.
(ii) XPA, RPA, and the TFIIH complex are recruited to the damage site after p8 stimulation of XPB ATPase and XPB-mediated unwinding;
XPB–XPD unwind DNA to create a bubble.
(iii) ERCC1-XPF and XPG are then recruited and incise 50 and 30, respectively, to the bubble junction, releasing an approximately 30
nucleotide stretch of DNA bearing the lesion.
(iv) Repair synthesis is carried out by the PCNA-dependent Pol d/3.
(v) The remaining nick is sealed by Ligase I or the XRCC1-Ligase IIIa complex (not shown).
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preservation of genetic integrity.104 Because accessibility of
the sister chromatid is crucial for HR (strand exchange dur-
ing HR is 100-fold more frequent between sister chroma-
tids than between disparate homologous chromosome re-
gions), this process takes place after DNA has been
replicated, i.e., in the S or G2 phase of the cell cycle.
Figure 3. Repair of DSBs
(A) Homologous recombination at two-ended DSBs: (i) Detection of DSB by the MRN complex and recruitment of ATM. Other repair and
cell-cycle checkpoint proteins are activated by ATM. (ii) 50–30 exonuclease resection of the DSB to generate a 30 single-stranded overhang.
MRE11 endonuclease may play a role in this process. (iii) Rad51-directed homology search, followed by strand invasion, displaces the
complementary region of the homolog (typically a sister chromatid) and creates a D-loop (open arrowhead). Rad51 is probably assisted
by RPA and other Rad family members, such as Rad52 and Rad54. (iv) Upon formation of a Holliday junction (gray arrowhead), the in-
vading strand can extend in both directions (note long arrows in v). (v) Extension of invading strand by a DNA polymerase can lead to
invasion of the homolog by the second end of the original DSB to form a double Holliday junction intermediate. (vi) Rad51C promotes the
resolution of the Holliday junctions to yield either crossover (vertical arrows) or non-crossover (horizontal arrowheads) recombination
products.
(B) Single-strand annealing (SSA): (i) Formation of a two-ended DSB between homologous repeat sequences (black and gray bars). (ii)
Exonuclease resects the ends to generate a 30 single-strand overhang, exposing the complementary regions. (iii) Alignment and Rad52-
dependent annealing of the repeat sequences leads to displacement of the 30 tail between the repeats or creation of a gap (not shown).
ERCC1/XPF is thought to digest 30-displaced tails. (iv) Ligation of ends regenerates the intact duplex and deletes the sequence between
the repeats.
(C) Homologous recombination at a one-ended DSB: (i) Reversal of a stalled replication fork on encountering an obstacle such as a lesion
or adduct in the template strand leads to formation of an intermediate. (ii) Endonuclease action on the intermediate can result in a
collapsed replication fork with a one-ended DSB. (iii) A 50–30 exonuclease resects the DSB to generate a 30 overhang capable of stand
invasion. (iv) Rad51 directs strand invasion into the fully copied complementary duplex, producing a D loop structure and Holliday junc-
tion (see panel [A]) necessary to ultimately restore the replication fork. (v) Resolution of the recombination intermediate can occur
either via crossover (vertical arrows) or non-crossover (horizontal arrows) events to yield recombinant products.
(D) Non-homologous end-joining (NHEJ): (i) The Ku70-80 heterodimer binds each end of a two-ended DSB, aligns them, and recruits
DNA-PK and its cofactor inositol-6 phosphate (IP6) to form a bridging and signaling complex. (ii) Noncomplementary ends at the DSB
may be processed by Artemis exonuclease, MRN complex, or the FEN-1 nuclease to reveal microhomology or to create ligatable ends.
Gaps can be filled by Pol m to generate ligatable nicks, and other repair enzymes such as PNKP can function to generate conventional
30 hydroxyl or 50 phosphate termini. (iii) The processed DSB is then sealed by the XRCC4-LigaseIV tetramer to create an intact duplex.
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Conventional two-ended HR is initiated by recognition
of the DSB by the MRN complex comprised of the 30–50
exonuclease MRE11A (MIM 600814), the Rad50 (MIM
604040) ATPase, and the regulatory protein defective
in Nijmegen breakage syndrome (NBS1 [MIM
602667]).105,106 This complex acts as a break sensor and
recruits the protein kinase ataxia telangiectasia mutated
(ATM [MIM 607585]) to the site of the damage.105,107,108
Once recruited and activated, ATM signals to cell-cycle-
checkpoint proteins, chromatin-remodeling factors, and
other DNA-repair components to halt ongoing replication
and execute break resolution. We emphasize that there is
distinction between components that function to elicit
a DNA-damage response (e.g., ATM) and those compo-
nents that function in DSB resolution.
The ﬁrst step in the repair of DSBs by HR is a 50–30 exonu-
clease-directed resection to produce a 30 single-stranded
DNA overhang. The exact identity of the nuclease is un-
known, although studies suggest that the MRN nuclease
complex might be involved as a 50 endonuclease.105,109
Once generated, the single-stranded overhang is resolved
either by genetic exchange with a sister chromatid or by
SSA (see below), both of which are HR events (Figures 3A
and 3B). Strand invasion, as the name suggests, involves
invasion of the 30 end of the single-stranded DNA over-
hang into the region of complementarity in the intact sis-
ter chromatid (Figure 3A). This is directed by Rad51 (MIM
179617)—the human homolog of the E. coli RecA pro-
tein—which forms a nucleoprotein ﬁlament that directs
homology search, strand pairing, and ultimately, invasion
of the homologous chromosome.110–112 Several Rad family
members, such as Rad51B (MIM 602940), Rad51C (MIM
602774), Rad51D (MIM 602954), XRCC2 (MIM 600375),
XRCC3 (MIM 600675), Rad54 (MIM 603615), and Rad52
(MIM 60392), along with RPA, are thought to play roles
in assisting Rad51 in the process.113 During strand inva-
sion (see details in Figure 3A), Rad51 promotes the forma-
tion of the classic D-loop structure (step iii) and creates
a four-stranded Holliday junction intermediate,114 i.e.,
the site where the strands crossover (step iv). Subsequently,
the invading strand is extended by a DNA polymerase,
most likely polymerase h (POLH [MIM 603968]).115 Reso-
lution of the Holliday junction is reported to occur via
a Rad51C- and XRCC3 directed mechanism, leading to
the formation of a crossover or non-crossover recombina-
tion product (Figure 3A, step vi).104,116–118 A number of nu-
cleases and helicases, such as the RecQ family members
WRN (MIM 604611) and BLM (MIM 604610), which are
mutated in the premature aging syndromes Werner and
Bloom, respectively, are also reportedly involved in resolv-
ing Holliday junctions during the ﬁnal steps.119,120
Another form of two-ended DSB recombination is SSA.
This pathway resolves DSBs positioned between repeat se-
quences as shown in Figure 3B and does not require a sister
chromatid. SSA is directed by Rad52 and RPA binding to
the 30 end of the nuclease-derived single-stranded 30 over-
hang. If present, exposed repeat sequences upstream and
downstream of the DSB are aligned, potentially creating
30 ﬂap or short-gap intermediates. The nonhomologous
displaced 30 tails are most likely removed by the action of
ERCC1/XPF, which is homologous to the yeast RAD1
(MIM 603153)/RAD10 complex.121,122 After appropriate
nuclease and/or polymerase processing to create ligatable
nicks, the break is sealed by an as-yet-unidentiﬁed DNA
ligase. SSA leads to the deletion of the genetic information
between the repeats, making it error-prone.
HR at a one-ended DSB functions to resolve breaks that
are formed at collapsed replication forks (Figure 3C).
When a progressing fork encounters an obstacle, such as
a bulky adduct or a persisting SSB, on the template strand
of DNA, the fork may stall and form an intermediary struc-
ture. One such structure, the so called ‘‘chicken foot,’’
which arises from reversion of the stalled fork (Figure 3C,
step i), has been reported in bacteria, although not in
mammalian cells.123,124 Nevertheless, the intermediate
structure can be processed by endonucleases and/or heli-
cases to create a collapsed replication fork with a one-
ended DSB104 (Figure 3C, step ii). The end of this DSB
can then undergo exonuclease resection to generate a 30
single-stranded overhang, which is used by Rad51 and
the related HR proteins to execute strand invasion
(Figure 3C, steps iii and iv) and the resolution of Holliday
junction(s) (Figure 3C, step v) as described above. For
a more detailed understanding of the various DSBR pro-
cesses, refer to the reviews by Helleday104 and Szostak
et al.125
NHEJ. In mammalian cells, two-ended DSBs can be re-
solved not only by HR or SSA (above) but also by NHEJ,
which involves direct end-to-end ligation, and at times,
limited processing (Figure 3D). This form of ‘‘repair’’ can
lead to the restoration of the original sequence or to the
addition or removal of anywhere from a few nucleotides
to several kilobases of DNA, making this an error-prone
response. NHEJ is the major DSBR pathway in the G1
phase of the cell cycle because a sister chromatid is not
needed or available for resolution.104,126 NHEJ is initiated
by the Ku70 (G22P1 [MIM 152690])-Ku80 (XRCC5 [MIM
194364]) heterodimer, which recognizes DSB ends, aligns
them, protects them from excessive degradation, and ulti-
mately prepares them for ligation. The Ku heterodimer
recruits the protein kinase DNA-PKcs (DNAPK1 [MIM
600899]) (and its cofactor inositol-6-phosphate) to estab-
lish a bridging and signaling complex that serves to recruit
speciﬁc repair factors.127–131 If complementary ends are
not present at the break, they can be subject to nucleolytic
degradation to create single-strand overhangs with short
stretches of micro-homology. This, and other end process-
ing events, are seemingly effected by the Artemis exonucle-
ase in association with DNA-PK, and possibly by the MRN
complex, the FEN1 nuclease, or the WRN/BLM heli-
cases.130 When necessary, based on its interactions with
Ku and the XRCC4 (MIM 194363)-LigaseIV (LIG4 [MIM
601837]) complex, polymerization of missing nucleotides
is performed by DNA Pol m (POLM [MIM 606344]).130–132
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When necessary, 30- or 50-blocking ends are also removed
to generate the 30 hydroxyl and 50 phosphate termini re-
quired for ligation, for instance, by the 30-DNA phospha-
tase/50-kinase (PNKP [MIM 605610]).104,127–131,133,134 The
XRCC4-LigaseIV tetramer is recruited to seal the
DSB.130,134 A recently identiﬁed component of NHEJ is
the Cernunnos-XLF (XRCC4-like factor) protein (NHEJ1
[MIM 611290]), which associates with the XRCC4/ligase
IV complex and stimulates its ligase activity in an un-
known manner.135
Inherited DNA-Repair Disorders with
Neurological Abnormalities
As is clear from the discussion above, there is considerable
crosstalk and overlap between the processes and enzymatic
components of repair, replication, recombination, and
transcription. In nervous tissue, where replication-depen-
dent recombinational repair is not possible because of
the non-dividing status of the cells, BER/SSBR, NER, and
possibly NHEJ assume a special signiﬁcance as gatekeepers
of genomic integrity. This is exempliﬁed by the recent ﬁnd-
ings that some autosomal-recessive ataxias with purely
neurodegenerative pathology (i.e., not accompanied by
genetic instability or cancer predisposition) arise from de-
fects in SSBR-related proteins. Interestingly, neurological
deﬁciencies arising from defects in NER or DSBR are often
accompanied by some form of genetic instability and
cancer. Reviewed next are some of the well-studied and
recently characterized ataxias and disorders with neurolog-
ical pathologies stemming from defects in SSBR, NER, or
DSBR components (Table 2).
1. SSBR-Associated Disorders
A few spinocerebellar recessive ataxias have recently been
linked to defects in the processing of SSB ends. Such disor-
ders include spinocerebellar ataxiawith axonal neuropathy
(SCAN1 [MIM 607250]) and ataxia with oculomotor apar-
axia type I (AOA1 [MIM 208920]). As discussed above,
SSBs are common endogenous lesions, arising as intermedi-
ates of speciﬁc metabolic processes or as products of ROS
attack of DNA. Ataxia with oculomotor apraxia type II
(AOA2 [MIM 606002]) and a speciﬁc case of amyotrophic
lateral sclerosis (ALS4 [MIM 602433]), which both arise
from a mutation in the SETX gene (MIM 608465), might
also involve a SSBR defect, although this has not been ex-
plicitly shown. Spinocerebellar ataxias are characterized
by early to late childhood onset of motor in-coordination
in speech, gait, balance, and gaze and, in some instances,
Table 2. Defective DNA Repair in Neurodegenerative Diseases
Neurodegenerative Disorder Affected Gene Encoded Protein
Affected Pathway
or Mechanism Phenotype and Pathology
spinocerebellar ataxia with
axonal neuropathy I (SCAN1)
TDP1 Tyrosyl phosphodiesterase 1 SSBR peripheral axonal motor and
sensory neuropathy
ataxia with occulomotor
apraxia type I (AOA1)
APTX Aprataxin SSBR cerebellar ataxia and atrophy,
peripheral neuropathy,
occulomotor apraxia
ataxia with occulomotor
apraxia type II (AOA2)
SETX Senataxin SSBR? spinocerebellar ataxia,
cerebellar atrophy, peripheral
neuropathy, oculomotor
apraxia
xeroderma pigmentosum XPA, XPB, XPC, XPD,
XPE, XPG, XPF
xeroderma
pigmentosa group
NER neurological symptoms like
microcephaly, progressive
mental deficiency and ataxia,
seen in a small fraction of XP
patients
POL h Polymerase eta
Cockayne syndrome CS-A, CS-B Cockayne syndrome A, B NER retinal degeneration, partial
deafness and facio-skeletol
and/or gait abnormalities,
neuronal dystrophy
XPB, XPD, XPG xeroderma pigmentosa group
Trichothiodystrophy (TTD) XPB, XPD xeroderma pigmentosa group NER microcephaly, ataxia, mild
mental retardation,
neurodysmyelination of
cerebrum white matter
TTD-A an 8 kDa TFIIH
complex member
ataxia telangiectasia (AT)
and ataxia telangiectasia-
like disorder (ATLD)
ATM and MRE11 Ataxia Telangiectasia
Mutated and MRE11
DSBR (signaling) progressive
neurodegeneration,
premature aging, ataxia,
Seckel syndrome ATR Ataxia Telangiectasia
and Rad3-related protein
DSBR (signaling) growth retardation,
dwarfism, microcephaly
Nijmegen breakage
syndrome (NBS)
NBS1 Nibrin DSBR microcephaly, growth
retardation
LigaseIV syndrome LIGIV LigaseIV DSBR growth retardation
NHEJ1 syndrome NHEJ1 XRCC4 like factor (XLF), also
called Cernunnos
DSBR microcephaly, growth
retardation
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mental retardation arising out of spinocerebellar axonal
and post-mitotic neuronal degeneration. In this section,
we discuss the above genetic disorders and their corre-
sponding gene and repair defects.
SCAN1. SCAN1 was ﬁrst identiﬁed in nine members of
a Saudi Arabian family and is characterized by cerebellar
ataxia and peripheral axonal motor and sensory neuropa-
thy that resembles Charcot-Marie-Tooth disease.136 Symp-
toms and pathology, which include ataxia, dystharia, mild
hypoalbuminaemia, mild hypercholesterolaemia, and sen-
sory loss, manifest around the second decade of life.137 An
interesting feature of this autosomal-recessive disorder is
that the symptoms are purely neurodegenerative, without
any cancer predisposition, suggesting selective assault on
nondividing cells.
SCAN1 arises by a homozygous mutation in the TDP1
gene. The speciﬁc mutation (A1478G) results in substitu-
tion of the conserved histidine residue 493 with arginine
in the active site of the protein.136 TDP1 normally removes
DNA-bound topoisomerase 1 (Top1 [MIM 126420]) mole-
cules that arise during abortive enzymatic reactions and is
thought to be part of the SSBR pathway.138–140 Top1, a pro-
tein involved in the regulation of DNA supercoiling during
transcription and replication, transiently breaks one strand
of DNA and in the process forms a covalent link with the 30
terminus.67,141 After strand cleavage to relieve DNA ten-
sion, the protein-DNA intermediate is typically released,
and the strand break is resealed. In the event of an incom-
plete reaction, whichmay occur when the Top1-DNA com-
plex is formed in thevicinity of aDNA lesion, suchas amod-
iﬁed base, gap, or nick or when cells are exposed to the
chemotherapeutic agent camptothecin, the topoisomerase
is irreversibly trapped onDNA, creating an obstacle for pro-
cesses such as replication and transcription.41,139 In most
situations, TDP1 will resolve the abortive phosphotyro-
sine-DNA linkage, releasing the Top1 protein (or a degrada-
tion product) and generating a SSB that can be processed by
components of BER/SSBR.142 The A1476G mutation leads
to an approximately 25-fold reduction in TDP1 enzyme ac-
tivity and results in the accumulation of Top1–DNA reac-
tion intermediates.143
Supporting the role of SSBR in Top1-DNA removal are
the following observations: (1) cells defective in XRCC1,
a key scaffold protein in BER/SSBR, are sensitive to campto-
thecin, a Top1 inhibitor,144,145 and (2) XRCC1’s protein
partner, Ligase IIIa, associates with TDP1, and together
the XRCC1-Ligase IIIa complex stimulates TDP1 activity
at 30-phosphotyrosine SSBs in vitro.73,146 Recent studies
by El Khamisy et al. found that SCAN1 lymphoblastoid
cells exhibit a delay in the removal of IR-induced SSBs
and accumulation of IR-induced Top1-DNA abortive com-
plexes.146 Additional evidence supporting a role of TDP1 in
neurodegeneration comes from the studies by Katyal et al.
on TDP1/ knockout mice. These animals show age-
dependent and progressive cerebellar atrophy, and their
cerebellar neurons and primary astrocytes are defective in
rapid repair of SSBs associated with Top1–DNA complexes
or oxidative DNA damage.147 This observation, combined
with the purely neurological pathology seen with SCAN1
patients, suggests that SSBs are particularly cytotoxic to
nondividing cells, perhaps even more so to neurons as a
result of their higher energy needs and elevated oxidative
stress.
We point out that SCAN1 is a disorder of a larger family
of related disorders, collectively termed spinocerebellar
ataxias (SCAs), encompassing at least 29 genetic loci.148
The so-called autosomal-dominant SCAs constitute a group
of progressive ataxias with some similarity in their neuro-
pathology, including olivopontocerebellar atrophy and
cell loss from the Purkinje layer. Some of the SCAs are
known to be caused by expansion of CAG trinucleotide
repeats in the coding region of the mutated gene; such re-
peats lead to abnormally long polyglutamine stretches in
the protein. None are conclusively or directly linked to
defects in DNA repair, although there has been some indi-
cation of a repair defect in Machado-Joseph disease (SCA3
[MIM 109150]). Speciﬁcally, the defective gene product,
MJD1 (or ataxin-3) (ATXN [MIM 607047]), interacts with
the human homologs of the yeast DNA-repair proteins
RAD23A (MIM 600061) and Rad23B (MIM 600062),
HR23A and HR23B.149 The dominant SCAs will not be cov-
ered further here, and the reader is directed to reviews by
Schols et al.150 and Paulson151 for additional details.
AOA1. First discovered in 1988 as a disorder with AT-like
symptomology, AOA1 is characterized by early-onset cere-
bellar ataxia and atrophy, marked loss of Purkinje cells and
peripheral nerve ﬁbers, degeneration of posterior columns
and spinocerebellar tracts, hypoalbuminaemia, and hyper-
cholesterolaemia.137,149 Unlike AT, yet similar to SCAN1,
AOA1 does not involve non-neurological features such as
cancer susceptibility and immunodeﬁciency.
The defective gene locus for AOA1 (APTX) was identiﬁed
in members of Portuguese and Japanese families indepen-
dently and was shown to map to chromosome 9p13.152
The gene product Aprataxin is a ubiquitously expressed,
novel member of the histidine triad (HIT) superfamily of
hydrolases/translocases.152,153 Two alternatively spliced
variants have been observed, the longer and more abun-
dant of which is a 342 aa protein that can be divided
into three domains based on sequence homology. First,
the N-terminal region shares homology with PNKP, a pro-
tein involved in SSBR and known to interact with other
SSBR proteins, i.e., XRCC1, Pol b and DNA Ligase IIIa.64
Aprataxin has itself been shown to interact with XRCC1
(SSBR) and XRCC4 (DSBR/NHEJ), as well as the strand-
break sensor poly (ADP-ribose) polymerase 1 (PARP1
[MIM 173870]).72,154 Second, the central region of Apra-
taxin harbors the histidine triad motif typical of the HIT
family members, which display nucleotide-binding and
hydrolase activities.155 Indeed, recombinant Aprataxin
has been shown to exhibit hydrolase activity on the aden-
osine-50-monophosphoramidate and diadenosine tetra-
phosphate substrates of the histidine triad nucleotide-
binding protein (HINT) and the fragile-HIT (FHIT)
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subfamily of the HIT proteins.156,157 Aprataxin was dem-
onstrated to hydrolyze obstructive 50 adenylate, as well as
30 phosphate and 30 phosphoglycolate, groups from SSBs
and thereby create ligatable DNA ends.66,158 Supporting
a role for Aprataxin in SSBR, AOA1 cells are hypersensitive
to agents that generate SSB damage, such as hydrogen per-
oxide and methymethane sulfonate (MMS), show elevated
levels of DNA SSBs, and are defective in the repair of these
breaks over time.159–161 Most of the mutations discovered
in AOA1 family members are conﬁned to the catalytic do-
main, rendering the protein enzymatically inactive. Fi-
nally, the carboxy terminus contains a divergent zinc-ﬁn-
ger motif that is involved in binding undamaged and
nicked adenylated duplex DNA substrates.152,156,162
AOA2. AOA2, which shares some neuropathology with
AOA1, is an early-onset (10–22 years of age) disorder char-
acterized by spinocerebellar ataxia with cerebellar atrophy,
peripheral neuropathy, oculomotor apraxia, loss of Pur-
kinje cells, mild ﬁbrous gliosis, and elevated serum a-feto-
protein. The disease was ﬁrst identiﬁed in members of
Japanese, Pakistani, and Israeli families.163 The gene defec-
tive in AOA2 (SETX) was localized to chromosome 9q34
and encodes a novel member of the superfamily 1 heli-
cases.163–165 Homology searches indicate that this protein,
Senataxin, is an ortholog of the yeast RNA helicase Sen1P
and is similar to the human helicases RENT1 (MIM
604030) and IGMBP2 (MIM 600502), both of which are
involved in aspects of RNA processing.163 Although nei-
ther helicase activity nor a speciﬁc role in SSBR has been
assigned to Senataxin, we have included AOA2 under the
SSBR-related disorders on the basis of the similarities in
clinical and cellular phenotypes to AOA1. In particular,
AOA2 cells show a similar pattern of sensitivity to the
SSB-inducing agents hydrogen peroxide and MMS (but
not to IR) and a higher basal level of oxidative DNA dam-
age (8-oxo-dG).166 The presence of a helicase domain sug-
gests a role in some aspect of nucleic acid metabolism,
perhaps the processing of oxidative DNA damage. Dis-
ease-associated mutations of Senataxin have been mapped
in several ethnically diverse families of AOA2 patients and
include missense, nonsense, and frameshift mutations,
many of which lead to a truncated product.163
Senataxin has also been implicated in a slowly progress-
ing form of amyotrophic lateral sclerosis (ALS) called Juve-
nile ALS or ALS4.167 ALS (or Lou Gehrig’s disease) was ﬁrst
described by Myrianthopoulos et al.168 as Charcot-Marie-
Tooth disease in a family with English ancestry. It is a het-
erogeneous group of progressive and lethal neurological
disorders that are characterized by degeneration and atro-
phy of motor neurons in the cerebellar cortex, spinal
cord, and brain stem; the result is paralysis and eventual
death by respiratory failure. Inheritance is autosomal dom-
inant, and symptoms manifest around the second decade
of life. Chen et al. identiﬁed 3 SETX missense mutations
in ALS4 individuals from three geographically diverse fam-
ilies. The mutations—one lies in the C-terminal helicase
domain of Senataxin and the two others reside in the
N-terminal putative protein-protein interaction domain—
are speculated to result in a partial-loss-of-function or
a toxic gain-of-function protein.169,170
2. NER-Associated Disorders
XP, CS, and Trichothiodystrophy (TTD) (TTDN1 [MIM
234050] and TTDP [MIM 601675]) constitute a spectrum
of NER-related disorders broadly characterized by a varying
level of photosensitivity, neurodevelopmental abnormali-
ties, and predisposition to cancer. An interesting feature
of this set of diseases is the overlap in genes involved in
the manifestation of the clinical phenotypes, whereby dif-
ferent mutations in the same gene give rise to CS, XP, TTD,
or a combination thereof. As will be discussed below, it
appears that the neurological dysfunction exhibited by
a sub-set of these patients arises from defective repair of
speciﬁc forms of endogenous DNA damage (possibly oxi-
dative lesions) and/or general failure of the transcriptional
machinery.
XP. XP was ﬁrst described in 1874 as an inherited syn-
drome largely affecting the skin. It constitutes a group of
autosomal-recessive disorders caused by mutations in the
XP gene family that participates in NER. The hallmarks of
XP include sensitivity to sunlight, severe sunburns upon
short exposure to UV light, excessively dry skin, freckles,
dark spots, and premature aging of the skin and eyes, along
with an increased risk for skin cancer. XP patients are more
than 1000-foldmore likely to develop cutaneous basal- and
squamous-cell carcinomas at sun-exposed areas (such as the
face, neck, and head) and are at increased risk for develop-
ing internal cancers by 20 years of age.171,172 Cells from
XP patients exhibit extreme sensitivity to UV radiation
and poor NER after exposure to UV radiation. Although
the typical features of classical XP are not related to neuro-
dysfunction, a small fraction of XP patients (about 20%)
develop neurological abnormalities, including microceph-
aly, progressive mental deﬁciency, ataxia, choreoathetosis,
and areﬂexia.173–176 Neuropathology in some patients in-
cludes a primary degeneration affecting large neurons in
the brain, spinal cord, and peripheral nervous system and
resulting in cortical atrophy, axonopathy, and glio-
sis.172,175,176
Themutant genes inXPwere identiﬁed as seven indepen-
dent complementationgroups (XPA-XPG)by fusion studies
that used cells defective in various aspects of repairing
UV-induced DNA damage (i.e., NER). A variant XPV group
was found to be associated with an NER-proﬁcient form of
XP, but this group maintained the characteristic skin sen-
sitivity to UV light. The genetic defect in XPV is linked to
Pol h, which is required for efﬁcient and accurate transle-
sion synthesis (TLS) past UV photoproducts.177 Cells from
these patients show enhanced arrest of DNA replication at
pyrimidine dimer sites and increased mutagenesis and re-
combination. Of the several mutations identiﬁed in POL
h, the majority result in severe truncations of the protein,
whereas others in the conserved catalytic domain of the
protein affect the TLS activity of the polymerase.178
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The complementation groups XPA, XPB, XPD, and XPG
have been associated with some form of neurological pa-
thology. Certain XPB, XPD, and XPGmutations also result
in adualXP/CSphenotype that displays differing degrees of
neuronal, developmental, and skin abnormalities and will
be discussed in detail in the section on CS below. XPA, in
combination with XPC, facilitates lesion recognition and
veriﬁcation during the early steps of NER and might also
play a role in conferring processivity to the XPF and XPG
nucleases.179,180 Several XPA deletions or splice-site muta-
tions that result in a frameshift have been reported in the
DNA-binding domain of the protein and are associated
with a neurological form of XP. Almost all of these muta-
tions seriously disrupt protein composition and/or struc-
ture and the ability of XPA to recognize lesions and initiate
NER.181 Several missense mutations have also been re-
ported in the C-terminal TFIIH-binding domain of XPA
and are associated with amuchmilder neurological pheno-
type. XPF mutations in humans are generally associated
with milder forms of XP, although one mutation has been
linked to a progeroid syndrome, which might result from
roles of NER proteins, e.g., XPF, in the repair of endogenous
DNA crosslinks.182 It is interesting to note that the XPF
knockout mouse exhibits a severe phenotype,183 which
might imply that ‘‘mild’’ XPF mutations compatible with
viability will be more ‘‘common’’ in humans. A recent
case of an inherited ERCC1 defect that is associatedwith se-
vere developmental failure and cerebro-oculo-facio-skeletal
syndrome (COFS4 [MIM 610758]) has been reported to
mimic the XPF cellular phenotypes in showing reduced
levels of ERCC1-XPF and a mild NER deﬁciency.84 A more
comprehensive analysis of the XP gene mutations is pre-
sented by Itin et al.184 and Cleaver et al.185 Finally, XPC
mutations have not directly been linked to a neurological
phenotype, yet one case of a splice-site mutation at exon
9 in the XPC gene has been reported in connection with
autism in a Korean subject.186
The defects described above are largely conﬁned to genes
that modulate mainly GGR. Evidence indicates that in
nondividing cells global DNA repair, particularly GGR, is
mostly conﬁned to actively transcribed gene regions, possi-
bly as a result of DNA accessibility and an effort to conserve
energy resources (for review see Nouspikel187). The conse-
quence of a repair deﬁcit in noncoding regions is that, in
the event of an unexpected checkpoint collapse, culminat-
ing in reentry into the cell cycle, attempted replication of
DNA would be crippled by the accumulated lesions. This
has in fact been speculated to be one of the reasons for
neuronal loss in certain neurodegenerative diseases187,188
andmight also explain theneuronal phenotypes associated
with certain cases of XP. However, it remains unclear how
this phenomenon would impact certain brain regions
selectively.
CS. First reported in 1936 by Edward Alfred Cockayne,
a British physician, CS is an early-onset, progressive neu-
rological disorder characterized by dwarﬁsm, microenca-
phaly, mental retardation, sensitivity to sunlight, retinal
degeneration, partial deafness, and facio-skeletal and/or
gait abnormalities, but no increased cancer incidence.189
In terms of its neuropathology, the CS brain shows in-
creased ﬁbrosis, neuronal dystrophy, and an accumulation
of senile plaques and/or neuroﬁbrillary tangles along with
progressive demyelination or dysmyelination.190 CS is di-
vided into two types: type A (CSA) and type B (CSB). CSA
is caused by mutations in the ERCC8 (MIM 609412)
gene, and CSB is caused by ERCC6 (MIM 609413) muta-
tions. The genes map to chromosome loci 5q12 (CSA
-ERCC8) and 10q11 (CSB -ERCC6)93,191 and fully comple-
ment the diagnostic UV-related defect in RNA-synthesis
recovery in the appropriate CS cell lines.192 Two clinical
variants of type B, the classic severe infantile variant and
COFS syndrome, are both reported to be linked to defects
in CSB.193 Several different mutations, including missense
mutations, nonsense mutations, frameshifts, insertions,
splice mutations, and polymorphs have been identiﬁed
in the CSA and CSB genes of an ethnically diverse group
of CS patients; the vast majority of these mutations lead
to a truncated protein product, and approximately 80%
affect CSB.194
CSA and CSB operate in TCR of UV adducts (reviewed in
Laine and Egly195), which explains the defect in RNA-
synthesis recovery after UV exposure of CS cells; GG-NER
is unaffected in CS.196,197 CSA is a 44 kDa protein that
interacts with CSB and other components of the transcrip-
tion or repair machinery; for example, such components
include XAB2, the p44 subunit of TFIIH, and the hyper-
phosphorylated form of RNAPII. CSA is needed for recruit-
ing the nucleosomal binding protein HMGN1 (MIM
163920), the XPA-binding protein (XAB2 [MIM 610815]),
and TFIIH to the stalled RNAPII and is linked to a ubiquitin
ligase complex that regulates CSB degradation and RNA
polymerase ubiquitylation during TCR.93,95,96,198,199 CSB
is a member of the SWI2/SNF2 superfamily and has
DNA-dependent ATPase and ATP-dependent chromatin-
remodeling activities.200 It interacts with RNAPII in vitro
and in vivo, stimulates elongation by RNAPII in vitro,
and is needed for assembly of the NER proteins and histone
acetyltransferase p300 (EP300 [MIM 602700]) at a stalled
RNAPII.97,98,102 Both CSA and CSB mutant cells are also
hypersensitive to oxidative stress and are defective in the
removal of certain oxidative lesions, such as 8-oxo-dG
and (50S)-8,50-cyclo 20-deoxyadenosine, suggesting that
these proteins might be involved in the processing of
oxidative DNA damage.100–102,201 Whereas 8-oxo-dG is
excised primarily by the classic BER pathway, the (50S)-8,
50-cyclo 20-deoxyadenosine lesion is corrected speciﬁcally
by NER. Although there is no direct evidence indicating
that cyclopurines are causative in neuronal cell loss, these
adducts are known to block transcription and could con-
tribute to the manifestation of the neurological disease
seen in some XP and possibly some CS patients.202 In addi-
tion, there is in vitro biochemical evidence that suggests
that the neurodegenerative phenotype of some XP pa-
tients might stem from a role of NER in the removal and
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repair of classic oxidative base lesions such as 8-oxo-dG
and thymine glycol.124
It is likely that the developmental and neurological de-
fects observed in CS (and probably XP) stem in part from
the inability to efﬁciently process endogenous DNA dam-
age from genes undergoing active transcription. However,
there is also evidence indicating that CSB plays a direct role
in regulating transcription. De Sanctis et al. demonstrated
that CSB cells showed an overall defect in the recruitment
of RNA Pol II and basal transcription factors after UV expo-
sure.203 The complexity and variation of traits observed
in CS patients might thus arise out of a combination of
transcription and DNA-repair defects.
It is noteworthy that traits of CS are observed in a frac-
tion of XP patients that harbor mutations in XPB, XPD,
or XPG, which participate in both TCR and GGR. Such in-
dividuals are reported as XP/CS and are characterized by
clinical phenotypes of both disorders. Speciﬁcally, patients
with XP/CS show the sun sensitivity and skin and eye de-
fects of XP and CS’s neurological and somatic features,
such as short stature and developmental abnormalities.
Neuropathology of XP/CS includes cerebellar and cerebral
atrophy, dysmyelination, calciﬁcation of basal ganglia, and
Purkinje neuron degeneration.174
XPB (or ERCC3 [MIM 133510]) maps to chromosome
2q21 and encodes an ATP-dependent 30-50 helicase,204 and
XPD (or ERCC2 [MIM 126340]) maps to chromosome
19q13.2 and encodes a 50-30 helicase.205,206 Both XPB and
XPDaremembersof the transcriptioncomplexTFIIH, a cen-
tral member of the transcriptional machinery, and are in-
volved in basal transcription as well as NER. Mutations in
XPB associatedwith CS have been reported in four families,
and each leads to a truncation of the protein’s C-terminal
end, which harbors the critical helicase motifs. Cells from
these patients have reduced XPB protein and are defective
in post-UV RNA synthesis and DNA repair as measured by
unscheduled DNA synthesis.207,208 In vitro studies on two
of themutant XPB proteins immunoprecipitated from cells
of XPB-CS patients indicate that defective promoter open-
ing and reduced transcription by TFIIH might be responsi-
ble for the observed phenotypes.207 Additionally, one of
the mutations was shown to weaken the interaction
of XPB with p52, which is speculated to be a regulator of
XPB ATPase activity.209 A tenth subunit of TFIIH, p8-TTD-
A, which is mutated in a subset of TTD cases (see more be-
low), has also been shown to regulate XPB ATPase activity
and hence DNA unwinding at the lesion.82,210 Thus, the
complexity and variation of symptoms in XPB patients
can probably be attributed to the disruption of one or
more of these interactions. The nature of the disruption(s)
would lead to variable disassembly of the TFIIH complex
and in turn differentially affect transcription and/or NER
responses.
XPD interacts with p44, a TFIIH core subunit that stim-
ulates XPD helicase activity,211 and with the Cdk2 activat-
ing kinase (CAK) complex.212 The latter association sug-
gests that XPD mediates binding of CAK to the core
TFIIH.XPDmutations at the C-terminal end of the protein,
which is the interaction site for p44, have been reported in
XP/CS patients. Studies of one such XPD mutant protein
revealed a drop in intrinsic helicase and Cdk7-dependent
kinase activities in affected cells, leading to the hypothesis
that such mutations affect TFIIH stoichiometry and result
in decreased transcription and defective NER.207,211 An
N-terminal mutation has also been reported in two new
XPD-CS patients. Cells from these individuals exhibit re-
duced levels of TFIIH, a characteristic of XP/CS,213 and ran-
dom DNA breakage at sites distant from the actual damage
after UV irradiation, a feature previously observed in two
reported XPD/CS cases and one that is presumably respon-
sible for the extreme UV sensitivity observed in these
patients.214
Anadditional component reported to supportCAK-TFIIH
assembly is the ERCC5 (MIM 133530) gene product,
XPG.215 XPG, which maps to chromosome 13q32-33, con-
stitutes another XP/CS complementation group. The gene
encodes an endonuclease that facilitates removal of adducts
by incising 30 to the damage during classic NER.87,216 Sev-
eral missense and nonsense XPG mutations that result in
inactive or severely truncated proteins have been found in
a diverse set of individuals with XP/CS.217 The truncation
mutants bring about the most severe phenotype, with
mortality in infancy or by early childhood. Emmert et al.
correlated severity of phenotype with the extent of XPG
transcript, where a milder phenotype corresponded to
ahigher level ofmRNA.Cells harboring a severely truncated
XPG with very low levels of transcript showed exception-
ally poor recovery of post-UV RNA synthesis, very low
post-UV cell survival, and impaired DNA repair.217 In addi-
tion to its direct role in NER, XPG has been suggested to
coordinate recognition of stalled transcription complexes
during TCR in concert with CSB and TFIIH.218 Recent stud-
ies by Ito et al. also documented an altered interaction be-
tween XPG-TFIIH and an increased disassociation of CAK
and XPD from the TFIIH core in cells from either XPG or
XPG-CS patients, suggesting that XPG may play a central
role in stabilizing these protein complexes.215 Finally, there
is some evidence that XPG might facilitate repair of oxida-
tive DNA damage, possibly by fostering the DNA-binding
and AP lyase activities of the glycosylase hNth1 during
BER.219 The severity of phenotype in XPG patients might
therefore be a combined result of the loss of excision repair,
transcription, and possibly, efﬁcient removal of oxidative
DNA lesions.
TTD. TTD completes the trilogy of neurological disorders
related to defects in NER. Tricho (Greek for hair)-thio (sul-
fur) dystrophy (faulty nourishment) aptly describes this
autosomal-recessive disorder characterized by low-sulfur
content, brittle hair, and variable neurological and so-
matic abnormalities. TTD defects include photosensitivity,
ichthyosiform erythroderma (ﬁsh-like scales on skin), and
progeria-like faces (faces that look prematurely aged), mi-
crocephaly, ataxia, mild mental retardation, neurodysmye-
lination of cerebrum white matter, and in some cases,
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calciﬁcation of the basal ganglia. On the basis of its clinical
phenotype, TTD can be divided into two groups, a non-
photosensitive groupwithout defects in repair and a photo-
sensitive group with defective NER. Cells from the photo-
sensitive group show impaired removal of UV lesions,
hypermutability, decreased unscheduled DNA synthesis,
and reduced survival after exposure to UV light. The sever-
ity of these phenotypes varies with the location of the
mutation and the gene affected.220,221 Within the photo-
sensitive category, three complementation groups, XPD,
XPB, and TTD-A, have been reported; 95% of the reported
cases belong to the XPD group.222
As inXPandXP/CS, amajority of theXPDmutations that
give rise to TTD are point mutations leading to a single
amino acid change located in the C-terminal portion of
the protein, where the substitution may affect interactions
with the p44 subunit of TFIIH.207,211 Approximately one
third of the XPD-TTD mutations are located within an N-
terminal hotspot and lead to an R112-to-H substitution in
the DNA-RNA helicase motif of the protein. Patients that
are homozygous for this mutation are severely defective in
DNA repair as measured by removal of cyclo pyrimidine
dimers, although the clinical phenotype is reported to be
mild.223–225 As in XP and XP/CS, XPB mutations are rare
in TTD. A T116P substitution has been reported in a pair
of TTD siblings and is associated with defective post-UV
survival, unscheduledDNAsynthesis, andcyclopyrimidine
dimer removal, yet imparts a mild clinical phenotype.204
The third complementation group, designated TTD-A
(MIM 608780), was ﬁrst identiﬁed in a patient whose cells
complemented all known XP groups, yet showed very low
levels of TFIIH.226 The gene product of TTD-Awas recently
identiﬁed and encodes p8, an 8 kDa TFIIH sub-unit that
contributes to the stability of the complex in vivo.210 As
noted above, p8 also facilitates duplex unwinding at the
DNA lesion and recruitment of XPA. All three TTD-Amuta-
tions reported thus far, as well as the XPD-TTDmutations,
result in substantially reduced TFIIH, which could originate
from disruption of the p8-XPB-XPD interactions. Of the
three TTD-A alterations, one maps to a region speculated
to play a role in protein-protein interactions, and the others
result in either the production of a protein lacking a 15 res-
idue conserved N-terminal region or complete loss of pro-
tein synthesis (via alteration of the initiator codon ATG to
ACG). Recent structure-function studies on p8 suggest
that the affected region could be central to its task because
deletion mutants lacking 10 or 20 amino-terminal residues
were found to be incapable of restoring theNER defects and
reduced TFIIH levels associated with TTD-A cells.210,227
3. DSB-Response-Associated Disorders
Studies have found that defects in several key participants
of the DSBR response are associated with various, and often
related, forms of neurodegenerative disease. As discussed
below, these include inherited genetic disorders arising
frommutations in proteins such asMRE11, NBS1, Cernun-
nos-XLF, Ligase IV, and the signaling phosphatidylinositol
3-kinase-like protein kinases (PIKKs), ATM and AT and
Rad3related (ATR [MIM 601215]). Each of these proteins
functions in differing aspects of DSB resolution and/or
DNA-damage-checkpoint responses. It is hypothesized
that the neurological dysfunction of the associated disor-
ders arises from (i) a defect in the processing of DSBs pre-
sumably by the NHEJ pathway and/or (ii) an inappropriate
DNA-damage response, quite possibly during neural devel-
opment.
The circumstances under which DSBs are formed in ter-
minally differentiated post-mitotic, nondividing cells are
not clearly understood. One possibility is that DNA meta-
bolic intermediates, oxidative modiﬁcations, and/or SSBs
are clustered at speciﬁc sites within post-mitotic cells, in
a fashion similar to the multiply damaged sites created
by IR.31,228,229 This could result in the generation of endog-
enous DNA DSBs, where even a single unrepaired DSB has
the potential to be lethal, as witnessed from studies in
yeast.230 A related thought is that in highly metabolic cells
such as neurons, the rates of formation of endogenous
DNA damage might be higher than the normal repair ca-
pacity, and these higher rates might result in a greater like-
lihood of the formation of clustered lesions, perhaps more
so in euchromatin domains. If DSBs are indeed formed,
then defects in neuronal cells in NHEJ would clearly give
rise to unwanted accumulation of these deleterious and cy-
totoxic damages. In neuronal cells lacking DSB-response
proteins, such as AT, neuronal cells might be incapable of
eliciting a proper genetic response, culminating ultimately
in cell death. It would be interesting to know in the future
if the disorders described below exhibit global defects in
general genome DNA repair, such as BER. Ongoing work
on DSB generation and damage responses in post-mitotic
cells will ultimately add to our current understanding of
the role of DNA strand breaks in the manifestation of neu-
rological disease.
ATandATLD (MIM604391). First designated AT by Boder
and Sedgwick,231 the disease is characterized by progressive
neurodegeneration; premature aging; predisposition to
cancer, particularly lymphomas and leukemias; and im-
munological and reproductive abnormalities. The most
obvious clinical features of AT are motor incoordination
(ataxia) and the appearance of clusters of blood vessels or
‘‘spider veins’’ (telangiectasia) on the whites of the eyes.
Some of the neurological features and neuropathology in-
clude progressive degeneration of cerebellar Purkinje and
granule cells and the resulting cerebellar ataxia and dys-
function, distal spinal muscular dystrophy, occulomotor
apraxia, dysarthria, dystonia, choreoathetosis, and oculo-
cutaneous telangiectasia.
The gene defective in AT, ATM, codes for a 350 kDa
member of the PIKKs family of kinases involved in signal
transduction and cell-cycle control.232 The MRN complex
recruits ATM to DSBs, where it acts as a sensor to activate
various downstream target proteins, such as NBS1 (see be-
low), p53 (MIM 19110), and BRCA1 (MIM 113707), which
function to mitigate checkpoint responses, repair, or
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apoptosis.107,233–235 A vast number of mutations, includ-
ing frameshifts, missense mutations, nonsense mutations,
and splicing mutations spanning the entire length of the
ATM gene have been identiﬁed in AT patients; most of
these lead to a truncated protein. Cells from AT patients
show radio-resistant DNA synthesis (reduced inhibition
of DNA synthesis as seen in normal cells after exposure
to low doses of radiation)236–238 and are defective in activa-
tion of the G1/S or G2/M checkpoint239–242 and the p53
pathway after radiation.243 The cancer predisposition of
AT patients, therefore, undoubtedly stems from the failure
of a functional, but overwhelmed, repair system to keep up
with the unchecked DNA replication; this failure then
leads to genomic instability in dividing cells. The neuro-
logical features of AT presumably arise from the appear-
ance of lethal DNA intermediates, e.g., DSBs (see above),
or from an inappropriate DNA-damage response.
ATLD, as the name suggests, is characterized by features
similar to those of AT, without being linked to mutations
in the ATM gene. This disorder was ﬁrst reported by Stewart
et al., who identiﬁed mutations in MRE11 in two families
initially classiﬁed as AT.244 Individuals from these families
exhibited a clinical phenotype and cellular features typical
of AT; such features included increased radiosensitivity and
spontaneously occurring chromosome aberrations in pe-
ripheral blood lymphocytes.MRE11 encodes a 30-to-50 exo-
nuclease, which in complex with NBS1 and Rad50 initiates
many forms of recombination, including NHEJ in certain
circumstances, and is involved in the maintenance of telo-
mere length.245 Studies have shown that MRE11 recruits
and activates ATM at DSBs and regulates DNA replication
at the S phase checkpoint in response to DNA dam-
age.107,108,246 A recurring mutation in MRE11 in ATLD is
the 1714C-Tmissensemutation that generates a premature
stop codon. Individuals from an Italian and an English
family were found to bear this mutation, and in all cases,
the transcript harboring the premature stop codon was
subject to ‘‘nonsense mediated decay’’ (a process by which
mRNA transcripts with a premature stop codon are marked
for degradation to prevent expression of erroneous or trun-
cated proteins that might be lethal to the cell).244,247 These
individuals, not surprisingly, are defective in expression
and function of the MRN complex and show impaired
ATM activity in response to IR. Interestingly, the clinical
phenotype in these individuals is mainly neurological,
and there is an absence ofmalignancy through their fourth
decade of life, suggesting that the mutation is selectively
detrimental to DNA-repair functions of the nervous
system.
Seckel Syndrome. Seckel syndrome (MIM 210600) is an
autosomal-recessive disorder caused by mutations in the
ATR gene. The disorder is characterized by growth retarda-
tion, dwarﬁsm,microcephaly withmental retardation, and
a ‘‘bird-headed’’ facial appearance.248 Although there is
some heterogeneity reported with respect to the defective
locus, studies in two consanguineous Pakistani families
in which this locus maps to chromosome 3q22.1q24
have identiﬁed mutations in the ATR kinase as the causa-
tive defect.249,250 O’Driscoll et al. reported an ATR splice-
site mutation, which led to reduced but residual levels of
normal transcript and protein.248 In contrast to ATM,
which functions predominantly in the IR-induced DSB re-
sponse, ATR is thought to be activated bymultiple forms of
DNA damage, including DSBs arising at stalled replication
forks, as well as, possibly, IR-induced lesions. Studies have
found that ATR, like ATM, can be recruited to IR-induced
DSBs in an MRN-dependent manner, suggesting that there
might be crosstalk and overlap between these two
kinases.251,252 Once triggered and recruited to a DSB, ATR
can phosphorylate and activate some of the same down-
stream ATM targets, including p53, Rad17 (MIM
603139), NBS1, and H2AX (MIM 601172), a variant form
of the histone H2A. The current data suggests that the neu-
rological phenotypes of Seckel syndrome patients, much
like AT patients, in all likelihood arise from an overall de-
fect in the DNA-damage response and the recruitment of
essential repair components to the site of the lesion.
NBS. NBS (MIM 251260), ﬁrst identiﬁed in 1981, is an
autosomal-recessive chromosomal-instability disorder
characterized by microcephaly, growth retardation, immu-
nodeﬁciency, and predisposition to cancer.253 It is pheno-
typically indistinguishable from the Berlin breakage syn-
drome but involves a separate complementation group.
Although cells from NBS and AT patients share many simi-
larities, e.g., hypersensitivity to IR, radio-resistant DNA
synthesis, and a deﬁciency in the S phase checkpoint, as
well as similar chromosome breakages and exchanges, the
clinical phenotypes of the two diseases are distinct. In par-
ticular, NBS patients show characteristic microcephaly
rarely seen inATanddonotdevelop ataxia or telangiectasia.
The gene defective in NBS was mapped to chromosome
locus 8q21, and the gene product was identiﬁed as nibrin/
p95 (NBS1), which is a critical component of DSBR.254–256
Speciﬁcally, NBS1, as part of the MRN complex, regulates
repair by activating and recruiting key enzymes and ki-
nases, suchasATM, to the site of aDSB.105TheNBS1protein
has an N-terminal forkhead-associated domain (FHA) and
a breast cancer C-terminal domain (BRCT), which binds
to phosphorylated H2AX at DSB ends.257 The C-terminal
portion of NBS1 contains the MRE11-binding site, and
the central region bears consensus sequences for phosphor-
ylation by ATM and ATR.109,258,259 Thus, through these
interactions, NBS1 mediates both cell-cycle control and
DSBR (HR and NHEJ) and also participates in telomere
maintenance.260
It follows that NBS1mutations that abrogate important
protein-protein interactions can lead to the same systemic
breakdown of the DNA-damage signaling mechanism and
cell-cycle control seen in AT. A mutation found in a vast
majority of NBS patients is the 657 del5 frameshift
mutation.256 A deletion of 5 nucleotides in exon 6, it results
in twodifferent truncationproducts by an alternative trans-
lation mechanism.260 One of these products, NBS170, is
found to associate with the MRN complex and is thought
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to be partially active. Consequently, patients homozygous
for this mutation display a milder phenotype than individ-
uals harboring more severe NBS1 gene alterations. Other
mutations in NBS1 have been reported over diverse geo-
graphical groups, and most lead to a truncated, nonfunc-
tional or dominant-negative protein.
LigaseIV Syndrome and NHEJ1 Syndrome. In contrast to
AT and Seckel syndrome, which seemingly arise out of de-
fective DNA-damage signaling, LigaseIV and NHEJ1 syn-
dromes presumably stem from an actual defect in the repair
of DSBs. These syndromes therefore represent a direct link
between DSBR and the manifestation of neurological
disease and suggest the possibility of DSBs in post-mitotic
cells, even though it is unclear how they might arise. The
LigaseIV syndrome is caused by mutations in the LIG4
gene.261 As described above, LigaseIV functions to seal DSB
ends during NHEJ. Several LIG4 mutations that disrupt
either the ligase domain or its interaction with XRCC4
have been identiﬁed.261,262 The clinical features of this syn-
drome are very similar to those of NBS and include immu-
nodeﬁciency and developmental and/or growth delay.
Fibroblasts from LIG4 patients maintain the pronounced
radiosensitivity and impaired DSB rejoining expected of
defective repair. The NHEJ1 syndrome is caused by muta-
tions in the recently identiﬁed NHEJ1 gene that encodes
the 33 kDa XRCC4-like factor (XLF), or Cernunnos. This
protein is reported to promote NHEJ via its interaction
with XRCC4 and LigaseIV.135,263 Buck et al. identiﬁed
mutations in theNHEJ1 gene from ﬁve patients with severe
combined immunodeﬁciency (SCID), microcephaly,
growth retardation, and sensitivity to IR. In a separate
patient, Ahnesorg et al. reported a frameshift mutation
that leads to a truncated protein with severely diminished
or almost no expression of XLF. Cells from this patient
were found to be radiosensitive and defective in NHEJ,
and both of these shortcomings were corrected by reintro-
duction of the wild-type XLF.135 Thus, on the basis of the
LigaseIV and NHEJ1 disorders discussed here, it seems pos-
sible that DSBs are formed and can persist in nondividing
cells and thus create transcription roadblocks that lead to
cell death and neurodegeneration.
Neurodegenerative Disorders Associated with
Oxidative Stress
The central nervous system (CNS) is extremely susceptible
to oxidative stress on account of its high metabolic rate.
Additionally, generation of free radicals during the process-
ing of dead neuronal debris by macrophages adds to the
pro-oxidant environment. These facts, coupled with the
lack of regenerative capacity of terminally differentiated
post-mitotic cells of the CNS,makes neurons a prime target
for accumulation of DNA damage and, ultimately, tissue at-
rophy. Consistently, several major neurodegenerative dis-
orders, such as Lou Gehrig’s disease, Alzheimer’s disease
(AD [MIM 104300]), Parkinson’s disease (PD [MIM
168600]), Huntington’s disease (HD [MIM 143100]), and
Friedreich’s ataxia (FRDA [MIM 229300]), display elevated
oxidative tension and are probably exacerbated by the ac-
cumulation of associated DNA damage. A brief summary of
these disorders is presented here, but for a more detailed
understanding, the reader is encouraged to access the re-
views cited below.
ALS1, an autosomal-dominant form of ALS, arises from
mutations in the copper-zinc superoxide dismutase (SOD-
1 [MIM 147450]) gene.264 SOD-1 codes for a 153 aa, ubiqui-
touslyexpressedprotein thatdismutates superoxide radicals
released during oxidative phosphorylation to hydrogen
peroxide and that makes up about 0.1%–0.2% of all CNS
protein.More than125mutations of SOD-1have been iden-
tiﬁed in familial ALS (FALS) patients (20%–25%of all cases);
these include missense, nonsense, and deletion mutations,
which produce a truncated protein.265,266 SOD-1, like Alsin
(MIM 606352), a 184 kDa GTPase mutated in ALS2 (MIM
205100) (a slowly progressing, autosomal-recessive form of
the disorder), functions tomaintain oxidative homeostasis.
ALS2 knockout mice exhibit age-dependent deﬁcits in mo-
tor coordination andmotor learning, and primary cultured
neurons from these mice are vulnerable to oxidative
stress.267 Studies have also implied that Alsin might play
a neuroprotective role, whereby overexpression of the
long-formof theprotein counteracts the cell deathobserved
with SOD1mutant mouse neuronal cells.268 Multiple ALS2
mutations have been associated with FALS, and most give
rise to a truncated protein.264–266 ALS is reviewed in more
detail by Lederer and Santama.269
Alzheimer’s is a progressive neurodegenerative disease
characterized by cognitive deterioration, including amne-
sia, aphasia, apraxia, agnosia, and dementia. The disorder
is thought to be caused by misfolding of b-amyloid and
Tau proteins, which aggregate and deposit as plaques and
neuroﬁbrillary tangles (NFTs) in AD brains.270–272 Both
the NFTs and Ab plaques are reported to be sites for redox
cycling and the generation of damaging free radicals.273,274
Indeed, brains of AD patients show detectable oxidative
damage (e.g., carbonyl- and acyl-modiﬁcations) within the
NFTs andAb plaques and increased levels of oxidative-stress
markers such as theDNAbase lesions 8-oxo-dG, 5-hydroxy-
cytosine and 5-hydroxy-adenine.275,276 A protein impli-
cated in the manifestation of AD is apolipoprotein E
(ApoE [MIM 10774]), which typically directs the transport
of lipoproteins into target cells via receptor-mediated endo-
cytosis.277 In addition,ApoEhasbeen shown invitro to che-
late redox-active metals such as iron and copper,273,275 and
elevated levels of both thesemetals havebeen found inneu-
ropil (i.e., the unmyelinated neuronal processes of the gray
matter) of AD patients with ApoE defects.275 Indeed, inher-
itance of a mutant ApoE E4 allele confers increased suscep-
tibility in many AD patients. Further discussion of the role
of oxidative stress in AD is reviewed by Smith et al.275
An increase in ROS and oxidative biomarkers, e.g., 8-oxo-
dG, lipid hydroperoxides,malonaldehdyes, and reactive car-
bonyl species, has been observed in the brains of PD pa-
tients.278,279 PD, which is characterized by muscle rigidity,
tremors, and in extreme cases, a loss of physical movement
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(akinesia), is causedbydegenerationofdopaminergic cells in
the brain’s susbtantia nigra, the region that controls
voluntary movement, produces the neurotransmitter dopa-
mine, and regulatesmood. In both AD and PD, it is not clear
whether the oxidative stress is the cause of the disease or
results because of the disease, as further discussed by
Jenner.280
FRDA is an autosomal-recessive disorder characterized by
progressive ataxia and loss of limb deep-tendon reﬂexes
(contraction of muscles in response to stimuli such as tap-
ping of muscle tendons). Most of the clinical features are
the result of degeneration and atrophy of sensory neurons,
spinal-cerebellar tracts, and sensory ﬁbers in the peripheral
nerves.281,282 The genetic defect underlying the disease re-
sults in reduced expression of a mitochondrial protein
called Frataxin (FXN [MIM 606829]), which plays a role
in mitochondrial energy activation and oxidative phos-
phorylation.282–284 Recent evidence suggests that Frataxin
might also function in ROS detoxiﬁcation via activation of
glutathione peroxidase and elevation of thiols, which act
as a chaperone for Fe(II) and a storage compartment for ex-
cess iron.284,285 In addition, Frataxin is speculated to play a
role in iron loading into Fe-S clusters, for instance into the
mitochondrial respiratory-chain complexes I and II/III.286
A defect in Fe loading is speculated to lead to free iron
overload, which promotes free-radical formation and oxi-
dative stress and ultimately leads to impaired oxidative
phosphorylation. For a more detailed review of the role
of oxidative stress in FRDA, refer to Butterﬁeld et al.287
HD is an autosomal-dominant disorder characterized by
involuntary choreiformmovements, loss of cognitive func-
tion, and amassive loss of neurons in the striatum.286,287 It
is caused by CAG trinucleotide expansion in the coding re-
gionof theHDgeneonchromosome4; this expansion leads
to a toxic glutamine-rich protein. Oxidative stress seems to
be a feature of the disease; patients harbor elevated levels of
oxidative biomarkers, such asmalondialdehyde, 3-nitrotyr-
osine, and heme oxygenase-1 and exhibit oxidative frag-
mentation of DNA in their cortical and striatal neu-
rons.287–289 Recent studies have demonstrated a more
direct link between oxidative stress and HD by correlating
CAG expansion to the activity of the BER enzyme OGG1.
Inparticular, theDNAglycosylaseOGG1 is proposed topro-
mote a ‘‘toxic oxidation cycle’’ in which strand displace-
ment and slippage during BER of oxidized bases can result
in expansionofCAGtriplets duringgap-ﬁlling synthesis.288
We emphasize that neurodegeneration is observed in other
CAG expansion diseases in which this strand-slippage
mechanism does not occur. For a more comprehensive
understanding of HD, refer to review by Walker.289
Concluding Remarks
We have provided a comprehensive summary of the vari-
ous forms of DNA damage and the systems that function
to repair them. As described above, heritable defects in sev-
eral components of these DNA-repair pathways, as well as
systems that protect against oxidative stress, have been
causally linked to cancer or neurological dysfunction. It
is presumed that the neuronal cell death in many of these
cases stems from the accumulation of DNA damage and
the accompanying interference of normal RNA transcrip-
tion, which leads to cell-death responses. Given the nondi-
viding nature of neurons, it is important to emphasize that
persistent DNA lesions cannot be resolved or removed by
the more universal pathway of replication-associated HR.
Furthermore, the disparate cancer susceptibility of the var-
ious DNA-repair disorders (Table 2) probably depends on
the nature of the persistent DNA damage and its intrinsic
genotoxic potential.
It is interesting that defects in genes involved in SSBR,
namelyAprataxin andTDP1,manifest exclusively asneuro-
degenerative disease, without a predisposition to cancer or
genetic instability. Conversely, an NER or DSBR defect ap-
pears to affect both dividing and nondividing tissues,
largely indiscriminately. These facts suggest that SSBR is
crucial to the maintenance of genomic integrity of nondi-
viding cells and that SSBs are not overtly genotoxic in repli-
cating tissue. The results also imply that helix-distorting
base adducts and complex DNA damages, such as DSBs,
are probably harmful to the genome integrity and func-
tional capacity of both developing and terminally differen-
tiated tissue. The pronounced sensitivity of nondividing
neuronal cells to DNA damage probably stems from (i) a
reliance on replication-independent repair pathways for
lesion removal (e.g., BER/SSBR, NER, and possibly NHEJ)
and (ii) theirhighmetabolicneeds and theassociatedoxida-
tive burden.
A noteworthy aspect of the presentation above is the dis-
tinct clinical pathologies andcellular phenotypes associated
withNERdisorders that stemfromdifferent, or in somecases
the same,mutationswithin a single gene (as seenwithXPD;
see the discussion of XP, CS-XP, and TTD-XP). Although it is
not completely clear why speciﬁc mutations within the
same gene give rise to multiple phenotypes, one simple ex-
planation is that the severity and spectrum of pathological
features is dictated by the nature of the mutation of the in-
dividual. That is to say, individuals harboring dominant-
negative or null alleles are likely to exhibit more profound
symptoms than individuals possessing partial-function al-
leles. Furthermore, different mutations within the same
geneare likely to lead todisparate effectsonenzymaticactiv-
ities and/or protein-partner interactions that would mani-
fest uniquely in terms of clinical and cellular phenotypes.
In situations where distinguishing symptoms have been as-
sociated with individuals harboring the same mutation
within the same gene, it seems likely that the overall genetic
composition of the individual (i.e., modiﬁer genes) would
dictate the pathological outcome. Given the complex cross-
talk and inter-dependence of repair and the replication and
transcriptional machinery, it seems reasonable that slight
variations in protein function or interactions might arise
from different mutations in the same gene and lead to
a broad spectrumof disorderswith suchdistinct yet overlap-
ping characteristics.
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Finally, it is worth mentioning that in addition to the
diseases above, several premature aging disorders exhibit
neurological defects that are linked to impaired DNA repair
and/or DNA processing. Some of the well-studied progerias
include the Werner, Bloom, and Rothmond Thompson
syndromes (RTS [MIM 268400]) caused by mutations in
the RecQ family of helicases, which have multiple roles
in facilitating DNA transactions.290,291 In addition, defec-
tive DNA repair is associated with other disorders, such
as Fanconi Anemia (FA [MIM 227650]), which stems
from mutations in the FANC gene family.290 The coming
years will prove especially important in unraveling some
of the underlying mechanisms and crosstalk between
repair pathways that synchronize to maintain genomic
integrity in both dividing and nondividing cells.
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